Biology of Blood and Marrow Transplantation
Volume 15, Issue 9 , Pages 1108-1115 , September 2009

Lymphocyte Recovery Is a Major Determinant of Outcome after Matched Unrelated Myeloablative Transplantation for Myelogenous Malignancies

  • Katarina Le Blanc

      Affiliations

    • Division of Clinical Immunology and Transfusion Medicine, Karolinska Institutet, Stockholm, Sweden
    • Hematology Center, Karolinska University Hospital Huddinge, Stockholm, Sweden
    • Corresponding Author InformationCorrespondence and reprint requests: Katarina Le Blanc, MD, PhD, Division of Clinical Immunology and Transfusion Medicine, F79, Karolinska University Hospital, Huddinge, SE-141 86 Stockholm, Sweden.
    • ,
  • A. John Barrett

      Affiliations

    • Stem Cell Allotransplantation Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland
    • ,
  • Marie Schaffer, PhD

      Affiliations

    • Division of Clinical Immunology and Transfusion Medicine, Karolinska Institutet, Stockholm, Sweden
    • ,
  • Hans Hägglund

      Affiliations

    • Hematology Center, Karolinska University Hospital Huddinge, Stockholm, Sweden
    • Division of Hematology, Karolinska Institutet, Stockholm, Sweden
    • ,
  • Per Ljungman

      Affiliations

    • Hematology Center, Karolinska University Hospital Huddinge, Stockholm, Sweden
    • Division of Hematology, Karolinska Institutet, Stockholm, Sweden
    • ,
  • Olle Ringdén

      Affiliations

    • Division of Clinical Immunology and Transfusion Medicine, Karolinska Institutet, Stockholm, Sweden
    • Center for Allogeneic Stem Cell Research, Karolinska University Hospital Huddinge, Stockholm, Sweden
    • ,
  • Mats Remberger

      Affiliations

    • Division of Clinical Immunology and Transfusion Medicine, Karolinska Institutet, Stockholm, Sweden

Received 19 February 2009 ,Accepted 15 May 2009.

  • Image Result

    Distribution of absolute lymphocyte counts at day 30 after unrelated donor HSCT. Figures are given as ×109/L.

    Distribution of absolute lymphocyte counts at day 30 after unrelated donor HSCT. Figures are given as ×109/L.

  • Image Result

    (a) Cumulative incidence of treatment-related mortality (TRM), (b) Actuarial relapse free survival (RFS) for all patients, (c) Cumulative incidence of aGVHD grades II-IV of patients with an absolute l

    (a) Cumulative incidence of treatment-related mortality (TRM), (b) Actuarial relapse free survival (RFS) for all patients, (c) Cumulative incidence of aGVHD grades II-IV of patients with an absolute lymphocyte count on day +30 (LC30) <0.2×109 (solid line), 0.2-1.0×109 (dotted line) and ≥1.0×109 (dashed line). (d) Actuarial RFS for 77 patients who did not develop aGvHD before day 30.

 Financial disclosure: See Acknowledgments on page 1114.

PII: S1083-8791(09)00254-7

doi: 10.1016/j.bbmt.2009.05.015

Biology of Blood and Marrow Transplantation
Volume 15, Issue 9 , Pages 1108-1115 , September 2009

Article Tools

* Image Usage & Resolution